Compare EPSN & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | TNXP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 198.6M |
| IPO Year | 2018 | 2008 |
| Metric | EPSN | TNXP |
|---|---|---|
| Price | $6.00 | $14.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 169.5K | ★ 377.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $4.20 | $11.60 |
| 52 Week High | $8.50 | $69.65 |
| Indicator | EPSN | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 58.85 |
| Support Level | $5.96 | $13.32 |
| Resistance Level | $6.50 | $20.36 |
| Average True Range (ATR) | 0.21 | 0.74 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 55.77 | 84.59 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.